(E)-6-(3,3-difluoroazetidin-1-yl)-2-methylhex-4-en-3-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-6-(3,3-difluoroazetidin-1-yl)-2-methylhex-4-en-3-one
• 化学式: C₁₀H₁₅F₂NO
• 分子量: 203.23
• InChiKey: HJYVNQFHGWYKMD-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
  申请人：AMGEN INC.

  公开号：US20180177767A1

  公开（公告）日：2018-06-28

  Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供了KRAS G12C抑制剂，其组成，以及使用方法。这些抑制剂对治疗多种疾病有用，包括胰腺癌、结直肠癌和肺癌。
• Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
  申请人：Hodous Brian L.

  公开号：US20140162983A1

  公开（公告）日：2014-06-12

  The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

  本发明提供了新型嘧啶和吡啶化合物，其符合公式（I），公式（II），公式（III），公式（IV）和公式（V），以及它们的制备和用于治疗高增殖性疾病，包括但不限于癌症，狼疮，过敏性疾病，Sjogren's病和类风湿性关节炎。在优选实施例中，本发明描述了不可逆激酶抑制剂，包括但不限于布鲁顿酪氨酸激酶抑制剂。
• COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
  申请人：Merck Patent GmbH

  公开号：US20150259363A1

  公开（公告）日：2015-09-17

  The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

  本发明提供了新的嘧啶和吡啶化合物，包括式(I)、式(II)、式(III)、式(IV)和式(V)，以及它们的制备和用于治疗高增殖性疾病，包括但不限于癌症、狼疮、过敏性疾病、干燥综合症和类风湿性关节炎。在优选实施例中，本发明描述了不可逆激酶抑制剂，包括但不限于布鲁顿酪氨酸激酶抑制剂。
• BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER
  申请人：Amgen Inc.

  公开号：EP4001269A1

  公开（公告）日：2022-05-25

  Provided herein are compounds of formulae (I), (II), (III), (III´), (IV), (IV´) and (V): as KRAS G12C inhibitors for use in treating cancer, such as e.g. pancreatic, colorectal and lung cancer. Preferred compounds are e.g. benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives. An exemplary compound is e.g. 1-(4-(6-(2-bromo-5-hydroxyphenyl)-5-chloro-7-fluorobenzo[c]isothiazol-3-yl)piperazin-1-yl)prop-2-en-1-one (example 1-1):

  这里提供的是式 (I)、(II)、(III)、(III´)、(IV)、(IV´) 和 (V) 的化合物： 作为 KRAS G12C 抑制剂用于治疗癌症，如胰腺癌、结直肠癌和肺癌。 首选化合物为苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物等。 例如，1-(4-(6-(2-溴-5-羟基苯基)-5-氯-7-氟苯并[c]异噻唑-3-基)哌嗪-1-基)丙-2-烯-1-酮（例 1-1）就是一种示例性化合物：
• Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
  申请人：Merck Patent GmbH

  公开号：US10016448B2

  公开（公告）日：2018-07-10

  The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

  本发明提供了根据式(I)、式(II)、式(III)、式(IV)和式(V)制造和使用的新型嘧啶和吡啶化合物，用于治疗过度增殖性疾病，包括但不限于癌症、狼疮、过敏性疾病、Sjogren病和类风湿性关节炎。在优选的实施方案中，本发明描述了不可逆激酶抑制剂，包括但不限于布鲁顿酪氨酸激酶抑制剂。